Rigel Pharmaceuticals (RIGL) Long-Term Deferred Tax (2025 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Long-Term Deferred Tax of $243.3 million for Q1 2026, down 1.05% quarter-over-quarter from $245.9 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Long-Term Deferred Tax (2025 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $243.3 million for Q1 2026.
- In Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $243.3 million; the TTM figure through Mar 2026 stood at $243.3 million (changed N/A YoY), while the FY2025 annual figure was $245.9 million, changed N/A from the prior year.
- Long-Term Deferred Tax for Q1 2026 stood at $243.3 million, down from $245.9 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $245.9 million in Q4 2025, with the low at $243.3 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 238.07 Mn |
| Mar 31, 2026 | 243.28 Mn |
| Dec 31, 2025 | 245.85 Mn |